ALSO NOTED: Millipore CEO gains $3.9M comp package;Terminal cancer patients enlisted in trials; and much more...

> It may not rival the big bucks earned by Big Pharma CEOs, but Millipore chief exec Martin Madaus took home a hefty pay package last year. He earned $3.9 million in compensation in 2007. That includes $742,307 in base pay, a bonus of $488,000 and options worth $2.6 million on the day they were granted. Report [1]

> Which drug exec gets paid 140 percent more than the median among his peers? Cephalon CEO Frank Baldino (photo [2]). He made a cool $13.5 million last year. That paycheck included a $1.2 million salary, $2.2 million in bonus, and $10.1 million in stock and options. Report [3]

> Mortality rates at 494 hospitals around the country that participated in clinical trials for acute coronary syndrome declined. Report [4]

> Frustrated by the long years of research needed to prove the effectiveness of a new cancer therapy, British officials have designated a network of 19 hospital units that will be allowed to administer early-stage experimental cancer drugs to terminal patients. Report [5]

> Big Pharma companies are often quick to turn their backs on a drug that doesn't deliver strong data. But a series of these failed development programs have been resurrected by scientists who decided to search for the kind of genetic biomarkers that would define a group of patients who would respond positively. Report [6]

> Manipulating insulin levels raises the level of the master gene-regulating protein SKN-1, significantly prolonging the lives of microscopic worms in one study. Report [7]

> HistoRx and Eli Lilly have extended their technology agreement. Story [8]

> Pfizer and GlaxoSmithKline have been marking up meds to increase their revenues, according to Thomson data. The two companies boosted wholesale prices by about 9 percent on their 10 best-sellers last year. Without those increases, Pfizer and GSK would have seen their sales drop by more than 10 percent. Report [9]

> Pfizer is suing for Lipitor protection until 2016. Report [10]

And Finally... Many in the medical community are at odds over the ethics of at-home bipolar gene tests currently on the market. Report [11]